Bacterial cell wall peptidoglycan and associated enzymes

Bacterial cell wall peptidoglycan (PG), also known as murein, is a vital structural component found in almost all bacteria, providing the mechanical strength necessary to withstand high internal osmotic pressure and maintain cell shape (NIH, 2024; Frontiers in Microbiology, 2021). It is a complex mesh-like polymer composed of glycan strands of alternating N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc), which are cross-linked by short peptide bridges (MDPI, 2024). The assembly of this structure is a multi-stage process involving a series of essential enzymes, including the cytoplasmic Mur ligases (MurA-F), the membrane-associated MraY and MurG, and the periplasmic penicillin-binding proteins (PBPs) that catalyze transglycosylation and transpeptidation (Frontiers in Microbiology, 2021; ACS, 2024). Because peptidoglycan and its biosynthetic machinery are unique to bacteria and absent in human cells, they represent one of the most effective and selective targets for antimicrobial therapy (NIH, 2024; Lumen Learning, 2024). Clinically important antibiotics, such as beta-lactams (e.g., penicillins and cephalosporins) and glycopeptides (e.g., vancomycin), exert their bactericidal effects by disrupting specific steps in peptidoglycan synthesis or assembly (StatPearls, 2024; MDPI, 2024). Beta-lactams bind to and inhibit PBPs, preventing the cross-linking of the cell wall, while glycopeptides sequester the D-alanyl-D-alanine terminus of peptidoglycan precursors to block polymerization (NIH, 2024; LibreTexts, 2025). Other agents like fosfomycin and cycloserine target earlier cytoplasmic stages of the pathway by inhibiting MurA and D-alanine ligase, respectively (Frontiers in Microbiology, 2021). Despite the success of these drugs, the rapid evolution of resistance mechanisms—such as the production of beta-lactamases, target site mutations (e.g., mecA), and the acquisition of alternative metabolic pathways (e.g., vanA)—poses a significant challenge to modern medicine (MDPI, 2024; NIH, 2024).

Other names

MureinPeptidoglycan biosynthesis pathwayCell wall synthesis machineryBacterial cell wall assembly complexPeptidoglycan layer

Inhibition of bacterial cell wall synthesis through multiple enzymatic and structural disruptions: beta-lactams (penicillins, cephalosporins, carbapenems, monobactams) covalently bind to and inhibit penicillin-binding proteins (PBPs), preventing the transpeptidation (cross-linking) of peptidoglycan strands; glycopeptides (vancomycin, teicoplanin) and lipoglycopeptides (dalbavancin) bind to the D-alanyl-D-alanine terminus of peptidoglycan precursors to sterically hinder transglycosylation and transpeptidation; fosfomycin inhibits the enzyme MurA to block the initial step of precursor synthesis; D-cycloserine inhibits alanine racemase and D-alanyl-D-alanine ligase; and bacitracin sequesters undecaprenyl pyrophosphate to prevent the recycling of the lipid carrier required for precursor transport (NIH, 2024; Frontiers in Microbiology, 2021; LibreTexts, 2025).